Your session is about to expire
← Back to Search
MRI Monitoring for Prostate Cancer
Study Summary
This trial looks at using MRI to see how well a cancer treatment is working for patients with prostate cancer who are being actively monitored but have not yet received treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My blood pressure is not higher than 160/100 mm Hg, or it's controlled with medication.I am fully active or restricted in physically strenuous activity but can do light work.I am fully active or restricted in physically strenuous activity but can do light work.I had a prostate biopsy within the last 14 days.My last prostate biopsy showed no signs of cancer.I have been on hormone therapy for prostate cancer.I have had radiation treatment for prostate cancer.My prostate cancer is confirmed and considered low to intermediate risk.The Cockcroft Gault equation is a way to estimate how well your kidneys are working.I am either planning to or currently under active surveillance for my condition.My kidneys work well enough, with a creatinine clearance of 50 mL/min or more.I have heart failure that affects my daily activities.
- Group 1: Diagnostic (HP C-13 MRI)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any available openings for patients who want to participate in this clinical trial?
"That is correct, the trial is still enrolling patients. According to the information on clinicaltrials.gov, this study was first posted on July 18th, 2018 and updated most recently on October 3rd, 2020. They are looking for a total of 60 participants at 1 location."
Does the FDA condone the therapeutic use of Hyperpolarized Carbon C 13 Pyruvate?
"Hyperpolarized Carbon C 13 Pyruvate is in Phase 2 of clinical trials, meaning that while there is evidence suggesting it is safe, none of the data collected supports efficacy."
How many total participants are needed for this clinical trial?
"Yes, that is accurate. As per the information available on clinicaltrials.gov, this study was first posted on 7/18/2018 and is currently recruiting patients. The trial needs to recruit 60 individuals from 1 site."
What is the purpose of this research?
"The goal of this study is to establish a correlation between intra-tumoral C-pyruvate and glutamate levels with Gleason grade. Additionally, the study seeks to understand variability in kPG levels within patients, incidence of adverse events, and intra-patient variability in kPL."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger